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A B S T R A C T   
Primary amyloidosis of the ureter is a rare disease that is difficult to distinguish from urothelial carcinoma. Only 
50 cases of primary ureter amyloidosis have been reported since it was first described in 1937. Of these, only five 
cases of ureter amyloidosis with osseous metaplasia were reported. In this study, we report the clinical pre-
sentation of ureter primary amyloidosis that presented as a mass with osseous metaplasia. The aim of this study is 
to provide clinicians with knowledge about the clinical/radiologic manifestation that raise the suspicion of 
amyloidosis, bearing in mind the importance of differentiating it from other “malignant” processes.   
1. Introduction 
Primary localized amyloidosis of the ureter is a rare disease that is 
clinically and radiographically difficult to distinguish from urothelial 
carcinoma.1 It occurs predominantly in females.1 The mean age at 
diagnosis is 58 years and most patients present with flank pain or he-
maturia. The majority of ureteric involvement (up to 60% of cases) was 
reported in the lower ureter, followed by the upper portion according to 
a report by Ding et al.2 Only 50 cases of primary ureteric amyloidosis 
have been reported since it was first described in 1937.2 Of these, only 
five cases of ureter amyloidosis with osseous metaplasia were reported. 
In this study, we report the clinical presentation and pathologic findings 
of primary amyloidosis in the ureter and demonstrate the unusual pre-
sentation of the primary amyloidosis of the ureter as a lobulated nodular 
mass and pertinent osseous metaplasia association. The aim of this case 
report is to provide clinicians with knowledge about the clin-
ical/radiologic manifestation that raise the suspicion of amyloidosis, 
bearing in mind the importance of differentiating it from other “malig-
nant” processes. 
2. Case presentation 
We report a case of 82-year-old female with past medical history of 
chronic diastolic heart failure, atrial fibrillation, and type 2 diabetes 
who presented with weakness and fatigue. A computed tomography 
(CT) scan of the abdomen/pelvis without contrast demonstrated an 
incidental finding of right ureteral mass with layering calculi concerning 
for neoplasm. The mass led to ureteral obstruction and right sided 
hydronephrosis. Urine culture grew E. coli. The patient underwent ure-
teroscopy with biopsy and stent placement. 
Under light microscopy, the specimen revealed amorphous, ho-
mogenous, eosinophilic extracellular material expanded lamina propria 
and muscularis propria extending to the adventitia. Osseous metaplasia 
was also apparent. Fig. 1. Congo red staining was positive with unique 
apple-green birefringence on polarization. Fig. 2. Unfortunately, the 
patient did not pursue further follow up. 
3. Discussion 
Primary localized amyloidosis in the ureter is a rare entity caused by 
extracellular deposition of insoluble fibrillary protein that may result in 
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severe organ dysfunction.1 Amyloidosis is classified based on the type of 
the involved amyloidogenic protein or based on tissue distribution.1 
Primary amyloidosis is usually defined as amyloid immunoglobulin light 
chain disease that could involve different organs typically affecting the 
skin, soft tissues, genitourinary system, respiratory system, and gastro-
intestinal tract. Primary amyloidosis of the genitourinary tract is rare 
and most reported in the bladder and the prostate. The etiology of 
localized amyloidosis is unknown. Several studies suggested that pri-
mary amyloidosis could be related to chronic inflammation, monoclonal 
proliferation, and local secretion of light chains. Light chains accumu-
lation may transform into amyloid by lysosomal degradation. 
Secondary amyloidosis is often a result of a separate disease process, 
usually an underlying long term inflammatory disease such as rheu-
matoid arthritis, tuberculosis, or Crohn’s disease. The kidney is the 
major involved organ in the genitourinary tract.3 Alternatively, sec-
ondary amyloidosis could be an indication of a neoplastic disorder such 
as multiple myeloma. Because the clinical and radiologic findings are 
non-specific, histopathologic examination of the tissue remains the gold 
standard. 
Amyloidosis, also named “The great imitator,” because its nonspe-
cific clinical presentation.4 Although gross hematuria is a common 
manifestation, clinical signs and symptoms of ureteral obstruction such 
as hydronephrosis and hydroureter should raise the suspicion for 
amyloidosis in the genitourinary tract. This consideration could help in 
the avoidance of unnecessary surgery. Two conservative approaches can 
be used to preserve renal functioning after confirming the appropriate 
diagnosis by pathologic examination. One treatment option is segmental 
resection of the ureter with end-to-end anastomosis, ureteral reim-
plantation, and auto transplantation. The other treatment option is with 
dimethyl sulfoxide (DMSO). 
Microscopically, the amyloid protein deposits in the tissue as an 
extracellular pale pink, homogenous, and hyaline acellular material on 
hematoxylin eosin staining, mostly deposited in vascular and peri-
vascular tissue.5 Congo-Red staining is generally recommended and 
reveals apple-green birefringence appearance under polarized light with 
high sensitivity and specificity.5 Despite the relatively straightforward 
pathologic diagnosis of amyloidosis, additional subtyping is required for 
guiding the treatment. This subtyping is achieved by laser microdis-
section, then analysis by liquid chromatography/mass spectrometry 
technology. This methodology has emerged as the preferred method of 
amyloid typing and has its value for both confirmation of the diagnosis 
and subtyping and characterizing the peptide composition of the amy-
loidogenic protein with high sensitivity and specificity. 
The differential diagnosis in this case included urothelial carcinoma, 
carcinoma in situ, and atypical reactive processes. Two interesting 
findings in our case were the presentation primary amyloid as a lobu-
lated nodular mass formation that was suspicious for malignancy and 
the apparent osseous metaplasia formation. Local resection is the rec-
ommended clinical approach after ruling out a systemic disease process. 
4. Conclusion 
Primary localized ureteral amyloidosis is a rare and benign condition 
with only 50 cases reported in the literature. We report the sixth case of 
localized ureteral amyloidosis with associated osseous metaplasia. Due 
to the similarities in clinical/radiologic presentation with urothelial 
malignancy, a high level of awareness of this entity is required by the 
clinicians and pathologist to achieve an accurate diagnosis and appro-
priate patient management. 
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Fig. 1. H&E stains amorphic and eosinophilic acellular material in the ure-
ter specimen. 
Fig. 2. Positive Congo Red staining consistent with the diagnosis of ureteric 
amyloidosis. (For interpretation of the references to colour in this figure legend, 
the reader is referred to the Web version of this article.) 
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